采纳股份(301122) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥97,688,323.42, a decrease of 16.14% compared to the same period last year[3] - Net profit attributable to shareholders was ¥24,253,171.39, down 41.39% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥19,051,968.88, reflecting a decline of 45.02% compared to the previous year[3] - Total revenue for Q3 2024 was CNY 292,116,185.53, a decrease of 0.5% compared to CNY 293,587,422.03 in Q3 2023[17] - Net profit for Q3 2024 was CNY 57,452,000.48, down 38.0% from CNY 92,694,882.59 in Q3 2023[18] - Total comprehensive income for the third quarter was CNY 57,452,032.79, a decrease of 38.0% compared to CNY 92,694,882.59 in the same period last year[19] - Basic and diluted earnings per share were both CNY 0.47, down from CNY 0.76 year-over-year, representing a decline of 38.2%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,911,508,701.38, a decrease of 0.91% from the end of the previous year[3] - The total assets as of September 30, 2024, were CNY 1,911,508,701.38, slightly down from CNY 1,929,096,040.45 at the beginning of the period[16] - The total liabilities decreased to CNY 96,363,374.74 from CNY 122,504,462.38, a decline of 21.4%[16] - The equity attributable to shareholders increased to CNY 1,815,145,347.66 from CNY 1,806,591,578.07, reflecting a growth of 0.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥85,277,615.90, a decrease of 8.56% compared to the same period last year[3] - Cash flow from operating activities generated a net amount of CNY 85,277,615.90, a decrease of 8.5% compared to CNY 93,260,150.48 in the previous year[20] - Cash inflow from sales of goods and services was CNY 308,028,803.51, an increase of 3.0% from CNY 297,182,345.45 in the prior year[20] - The net cash flow from investing activities was ¥61,213,591.44, a significant improvement compared to a negative cash flow of ¥103,612,048.18 in the same period last year[9] - Cash flow from investment activities showed a net inflow of CNY 61,213,591.44, a significant improvement from a net outflow of CNY 103,612,048.18 in the same period last year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,274, with the top 10 shareholders holding a combined 70.83% of shares[10] - The largest shareholder, Lu Jun, holds 28.29% of shares, amounting to 34,580,000 shares[10] - The second-largest shareholder, Lu Weiwei, holds 16.16% of shares, totaling 19,760,000 shares[10] - The top 10 unrestricted shareholders include CITIC Prudential Life Insurance Co., Ltd., holding 5.85% of shares[10] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[11] - The total number of preferred shareholders is not applicable, indicating no preferred shares are currently issued[12] Government and Regulatory Issues - The company is currently facing an import warning from the U.S. FDA regarding its subsidiary, which may significantly impact future revenue and profits[13] - The company is actively communicating with the FDA to resolve the import warning issue, but the timeline for resolution remains uncertain[13] - The company emphasizes the importance of investor caution due to potential risks associated with the FDA warning[13] Investment and Expenses - Investment income for the period was ¥13,854,162.52, a decrease of 31.38% year-on-year due to market interest rate fluctuations[8] - Research and development expenses rose to CNY 18,993,814.45, an increase of 24.5% compared to CNY 15,293,551.06 in the previous year[17] - The company received government subsidies amounting to ¥278,558.82 during the reporting period, contributing to its non-recurring gains[4] - The company paid CNY 48,898,263.20 in dividends, an increase of 15.0% from CNY 42,315,804.90 in the same period last year[21] - The company reported a decrease in tax refunds received, totaling CNY 23,232,693.74, down from CNY 37,951,745.90 year-over-year[20] - The company experienced a foreign exchange loss of CNY 144,110.75, contrasting with a gain of CNY 4,555,487.90 in the previous year[21] Inventory and Receivables - Accounts receivable decreased to CNY 63,888,111.45 from CNY 97,267,234.13, a decline of 34.3%[15] - Inventory decreased to CNY 76,452,844.22 from CNY 90,101,978.88, a reduction of 15.1%[15] - Cash and cash equivalents increased to CNY 275,633,116.58 from CNY 178,329,283.19 at the beginning of the period, representing a growth of 54.5%[15] - Cash and cash equivalents at the end of the period totaled CNY 275,633,116.58, down from CNY 306,926,775.86 at the end of the previous year[21]